Citation: Xiaolin Zhang, Xiuli Liu, Luhui Qin, Chao Tang, Yu Huo, Jinbin Wei, Ming Chen, Yutong Gao, Xiaoping Zhang, Yani Wu, Yongxiang Zhao, Renbin Huang, Liping Zhong, Bing Wang. Averrhoa carambola extractive inhibits breast cancer via regulating CEPT1 and LYPLA1[J]. Chinese Chemical Letters, ;2023, 34(3): 107618. doi: 10.1016/j.cclet.2022.06.041 shu

Averrhoa carambola extractive inhibits breast cancer via regulating CEPT1 and LYPLA1

Xiaolin Zhang ^{a, 1} ,
Xiuli Liu ^{b, 1} ,
Luhui Qin ^{a, 1} ,
Chao Tang ^{b, 1} ,
Yu Huo ^b ,
Jinbin Wei ^a ,
Ming Chen ^a ,
Yutong Gao ^a ,
Xiaoping Zhang ^a ,
Yani Wu ^a ,
Yongxiang Zhao ^b ,
Renbin Huang ^{a, *,} ,
Liping Zhong ^{b, *,} ,
Bing Wang ^{c, *,}

a.
Pharmaceutical College, Guangxi Medical University, Nanning 530021, China
b.
National Center for International Biotargeting Theranostics, Guangxi Key Laboratory of Biotargeting Theranostics, Collaborative Innovation Center for Targeting Tumor Theranostics, Guangxi Medical University, Nanning 530021, China
c.
Department of Spine Surgery, The Second Xiangya Hospital of Central South University, Changsha 410011, China

huangrenbin518@163.com

zhong_liping@163.com

wbxyeyy@csu.edu.cn

Received Date: 3 March 2022
Revised Date: 14 June 2022
Accepted Date: 15 June 2022
Available Online: 19 June 2022

Figures(4)

Liposomes have been widely exploited as a drug delivery system in treating tumors because of their advantage to enhance anti-tumor efficacy and reduce side effects. In this study, the tumor-targeted 2-dodecyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione (DMDD, i.e., Averrhoa carambola extractive) liposomes (HA/TN-DLP) were conducted and assessed. HA/TN-DLP showed controllable drug loading (up to 83%) with high stability. In vitro and in vivo studies showed good cell uptake behavior and high inhibition rate of breast cancer compared to free DMDD. HA/TN-DLP might be the suitable for DMDD due to its better advantages in delivery, penetrability, and targeting-tumor capability. For in vivo mouse model tests, HA/TN-DLP effectively inhibited tumor growth compared to free DMDD. Further analyses indicated that HA/TN-DLP inhibited the glycerophospholipid metabolism pathway by reducing the biosynthesis of phosphatidylcholine and 1-acyl-sn-glycero-3-phosphocholine through regulating the expressions of CEPT1 and LYPLA1, and inhibited tumor cell growth by regulating the PI3K/Akt and NF-κB signaling pathways. In conclusion, the obviously enhanced antitumor effect further demonstrated that HA/TN-DLP may be a promising tumor-targeting agent.
- DMDD,
- Breast cancer,
- Transcriptomics,
- Metabolomics,
- PI3K/Akt pathway,
- Glycerophospholipid metabolism pathway
1. [1]
  X. Jiang, H. Tang, T. Chen, J. Gynecol. Oncol. 29 (2018) e7. doi: 10.3802/jgo.2018.29.e7
2. [2]
  J. Huang, X. You, P. Xin, et al., Chin. Chem. Lett. 32 (2021) 1737–1742. doi: 10.1016/j.cclet.2020.12.006
3. [3]
  X. Zhang, X. Duan, Y. Hu, et al., Nano Today 37 (2021) 101098. doi: 10.1016/j.nantod.2021.101098
4. [4]
  X. You, L. Wang, L. Wang, et al., Adv. Funct. Mater. 31 (2021) 2100805. doi: 10.1002/adfm.202100805
5. [5]
  A. Aruffo, I. Stamenkovic, M. Melnick, et al., Cell 61 (1990) 1303–1313. doi: 10.1016/0092-8674(90)90694-A
6. [6]
  L.Y. Bourguignon, H. Zhu, L. Shao, et al., J. Biol. Chem. 275 (2000) 1829–1838. doi: 10.1074/jbc.275.3.1829
7. [7]
  C. Li, X. You, X. Xu, et al., Adv. Sci. 9 (2022) e2104134. doi: 10.1002/advs.202104134
8. [8]
  J. Luo, C. Zhang, R. Liu, et al., J. Funct. Foods 47 (2018) 127–135. doi: 10.1016/j.jff.2018.05.041
9. [9]
  X. Zhou, X. Wu, L. Qin, et al., Drug Des. Dev. Ther. 14 (2020) 2667–2684. doi: 10.2147/dddt.s237699
10. [10]
  C. Chen, Z. Nong, Q. Xie, et al., Sci. Rep. 7 (2017) 6704. doi: 10.1038/s41598-017-07162-3
11. [11]
  Q. Wen, X. Lin, Y. Liu, et al., Molecules 17 (2012) 12330–12340. doi: 10.3390/molecules171012330
12. [12]
  M. Pons, M. Foradada, J. Estelrich, Int. J. Pharmaceut. 95 (1993) 51–56. doi: 10.1016/0378-5173(93)90389-W
13. [13]
  S. Yu, K. Zhu, J. Chen, et al., Nat. Commun. 9 (2018) 3369. doi: 10.1109/cac.2018.8623753
14. [14]
  T. Jiang, Z. Zhang, Y. Zhang, et al., Biomaterials 33 (2012) 9246–9258. doi: 10.1016/j.biomaterials.2012.09.027
15. [15]
  N. Yerushalmi, A. Arad, R. Margalit., Arch. Biochem. Biophys. 313 (1994) 267–273. doi: 10.1006/abbi.1994.1387
16. [16]
  J. Liu, Y. Sun, X. Liu, AAPS PharmSciTech 21 (2020) 259. doi: 10.1208/s12249-020-01792-z
17. [17]
  T. Sun, J. Gao, D. Han, Drug Deliv. 26 (2019) 975–988. doi: 10.1080/10717544.2019.1667454
18. [18]
  R.W. Johnstone, A.A. Ruefli, S.W. Lowe, Cell 108 (2002) 153–164. doi: 10.1016/S0092-8674(02)00625-6
19. [19]
  J.M. Adams, S. Cory, Science 281 (1998) 1322. doi: 10.1126/science.281.5381.1322
20. [20]
  R.B. Cornell, N.D. Ridgway, Prog. Lipid Res. 59 (2015) 147–171. doi: 10.1016/j.plipres.2015.07.001
21. [21]
  J.R. Krycer, L.J. Sharpe, W. Luu, et al., Trends Endocrinol. Metab. 21 (2010) 268–276. doi: 10.1016/j.tem.2010.01.001
22. [22]
  D.K. Nomura, B.F. Cravatt, Lipid Metab. Cancer FEBS J. 1831 (2013) 1497–1498. doi: 10.1016/j.bbalip.2013.08.001
23. [23]
  T.C. Knauss, F.E. Jaffer, H.E. Abboud, J. Biol. Chem. 265 (1990) 14457–14463. doi: 10.1016/S0021-9258(18)77324-9
24. [24]
  A. Norambuena, C. Metz, L. Vicuña, et al., J. Biol. Chem. 284 (2009) 12670–12679. doi: 10.1074/jbc.M808949200
25. [25]
  R.L.B. Costa, H. Han, W.J. Gradishar, Breast Cancer Res. Treat. 169 (2018) 397–406. doi: 10.1007/s10549-018-4697-y
26. [26]
  P. Rusquec, C. Blonz, J.S. Frenel, Ther. Adv. Med. Oncol. 12 (2020) 1758835920940939. doi: 10.1177/1758835920940939
27. [27]
  J.C. Coffey, J. Wang, M.J.F. Smith, et al., J. Biol. Chem. 280 (2005) 20968–20977. doi: 10.1074/jbc.M414696200
28. [28]
  X. Zhen, H. Choi, J. Kim, et al., Biomolecules 10 (2020) 245. doi: 10.3390/biom10020245
29. [29]
  Z. Orlova, F. Pruefer, R.C. Oropeza, et al., Biochim. Biophys. Acta Mol. Cell Res. 1866 (2019) 598–611. doi: 10.1016/j.bbamcr.2019.01.002
1. [1]
  Yanhua Chen , Xian Ding , Jun Zhou , Zhaoying Wang , Yunhai Bo , Ying Hu , Qingce Zang , Jing Xu , Ruiping Zhang , Jiuming He , Fen Yang , Zeper Abliz . Plasma metabolomics combined with mass spectrometry imaging reveals crosstalk between tumor and plasma in gastric cancer genesis and metastasis. Chinese Chemical Letters, 2025, 36(1): 110351-. doi: 10.1016/j.cclet.2024.110351
2. [2]
  Xiaoxiao Wang , Bolun Wang , Fenfen Ji , Jie Yan , Jiacheng Fang , Doudou Zhang , Ji Xu , Jing Ji , Xinran Hao , Hemi Luan , Yanjun Hong , Shulan Qiu , Min Li , Zhu Yang , Wenlan Liu , Xiaodong Cai , Zongwei Cai . Discovery of plasma biomarkers for Parkinson’s disease diagnoses based on metabolomics and lipidomics. Chinese Chemical Letters, 2024, 35(11): 109653-. doi: 10.1016/j.cclet.2024.109653
3. [3]
  Xiongbo Song , Jinwen Xiao , Juan Wu , Li Sun , Long Chen . Decellularized amniotic membrane promotes the anti-inflammatory response of macrophages via PI3K/AKT/HIF-1α pathway. Chinese Chemical Letters, 2025, 36(1): 109844-. doi: 10.1016/j.cclet.2024.109844
4. [4]
  Jiangshan Xu , Weifei Zhang , Zhengwen Cai , Yong Li , Long Bai , Shaojingya Gao , Qiang Sun , Yunfeng Lin . Tetrahedron DNA nanostructure/iron-based nanomaterials for combined tumor therapy. Chinese Chemical Letters, 2024, 35(11): 109620-. doi: 10.1016/j.cclet.2024.109620
5. [5]
  Zimo Yang , Yan Tong , Yongbo Liu , Qianlong Liu , Zhihao Ni , Yuna He , Yu Rao . Developing selective PI3K degraders to modulate both kinase and non-kinase functions. Chinese Chemical Letters, 2024, 35(11): 109577-. doi: 10.1016/j.cclet.2024.109577
6. [6]
  Jialin Xie , Qing Feng , Zhen Li , Jinyi Yang , Min Liu , Wei Qi . Life’s Guardian Angel: Progesterone. University Chemistry, 2024, 39(10): 416-419. doi: 10.12461/PKU.DXHX202403068
7. [7]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
8. [8]
  Kunya Wang , Bingyu Liu , Daojiang Yan , Jian Bai , Haibo Yu , Youcai Hu . Full biosynthetic pathway of pyrrolobenzoxazines. Chinese Chemical Letters, 2025, 36(1): 109811-. doi: 10.1016/j.cclet.2024.109811
9. [9]
  Jindian Duan , Xiaojuan Ding , Pui Ying Choy , Binyan Xu , Luchao Li , Hong Qin , Zheng Fang , Fuk Yee Kwong , Kai Guo . Oxidative spirolactonisation for modular access of γ-spirolactones via a radical tandem annulation pathway. Chinese Chemical Letters, 2024, 35(10): 109565-. doi: 10.1016/j.cclet.2024.109565
10. [10]
  Aolei Tan , Xiaoxiao Ma . Exploring the functional roles of small-molecule metabolites in disease research: Recent advancements in metabolomics. Chinese Chemical Letters, 2024, 35(8): 109276-. doi: 10.1016/j.cclet.2023.109276
11. [11]
  Yao-Hua Gu , Yu Chen , Qing Li , Neng-Bin Xie , Xue Xing , Jun Xiong , Min Hu , Tian-Zhou Li , Ke-Yu Yuan , Yu Liu , Tang Tang , Fan He , Bi-Feng Yuan . Metabolome profiling by widely-targeted metabolomics and biomarker panel selection using machine-learning for patients in different stages of chronic kidney disease. Chinese Chemical Letters, 2024, 35(11): 109627-. doi: 10.1016/j.cclet.2024.109627
12. [12]
  Huaran Zhang , Yuting Huang , Yingjie Tang , Dekun Kong , Yi Zou . Genome mining of multi-substituted alkylresorcinols from a hybrid highly reducing- and type Ⅲ- polyketide pathway. Chinese Chemical Letters, 2024, 35(7): 108968-. doi: 10.1016/j.cclet.2023.108968
13. [13]
  Ting Li , Xinxin Zheng , Lejing Qu , Yuanyuan Ou , Sai Qiao , Xue Zhao , Yajun Zhang , Xinfeng Zhao , Qian Li . A chromatographic method for pursuing potential GPCR ligands with the capacity to characterize their intrinsic activities of regulating downstream signaling pathway. Chinese Chemical Letters, 2024, 35(10): 109792-. doi: 10.1016/j.cclet.2024.109792
14. [14]
  Yudi Cheng , Xiao Wang , Jiao Chen , Zihan Zhang , Jiadong Ou , Mengyao She , Fulin Chen , Jianli Li . A near-infrared fluorescent probe for visualizing transformation pathway of Cys/Hcy and H₂S and its applications in living system. Chinese Chemical Letters, 2024, 35(5): 109156-. doi: 10.1016/j.cclet.2023.109156
15. [15]
  Weixu Li , Yuexin Wang , Lin Li , Xinyi Huang , Mengdi Liu , Bo Gui , Xianjun Lang , Cheng Wang . Promoting energy transfer pathway in porphyrin-based sp2 carbon-conjugated covalent organic frameworks for selective photocatalytic oxidation of sulfide. Chinese Journal of Structural Chemistry, 2024, 43(7): 100299-100299. doi: 10.1016/j.cjsc.2024.100299
16. [16]
  Qinyu Zhao , Yunchao Zhao , Songjing Zhong , Zhaoyang Yue , Zhuoheng Jiang , Shaobo Wang , Quanhong Hu , Shuncheng Yao , Kaikai Wen , Linlin Li . Urchin-like piezoelectric ZnSnO₃/Cu₃P p-n heterojunction for enhanced cancer sonodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109644-. doi: 10.1016/j.cclet.2024.109644
17. [17]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
18. [18]
  Kun Zou , Yihang Xiao , Jinyu Yang , Mingxuan Wu . Facile semisynthesis of histone H3 enables nucleosome probes for investigation of histone H3K79 modifications. Chinese Chemical Letters, 2024, 35(10): 109497-. doi: 10.1016/j.cclet.2024.109497
19. [19]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
20. [20]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110

Get Citation

PDF

XML

Metrics

PDF Downloads(5)
Abstract views(333)
HTML views(40)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142